Genzyme/Sanofi-Aventis
On February 16 2011, Genzyme Corporation (Nasdaq: GENZ) confirmed a definitive agreement to be acquired by Sanofi-aventis (NYSE: SNY) for $74.00 per share in cash, or approximately $20.1 billion, plus one Contingent Value Right.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
-
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
-
Sanofi (SNY) Requests Date of Shareholder Written Consent from Medivation (MDVN) to Remove, Replace Directors
-
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
-
Medivation (MDVN) Announces Filing of Consent Revocation Statement in Response to Sanofi (SNY)
-
Medivation Files Preliminary Consent Revocation Statement
-
Sanofi (SNY) Announces Filing of Consent Solicitation to Remove, Replace Medivation's (MDVN) Board
-
Sanofi Files Consent Solicitation To Remove and Replace Medivation's Board
-
Sanofi (SNY) Files for HSR Notification Regarding Proposed Acquisition of Medivation (MDVN)
-
Sanofi Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Medivation
-
Sanofi (SNY) Sends New Letter to Medivation (MDVN) Board; Says Shareholders Support Deal
-
Sanofi Sends Letter to Medivation's Board of Directors
-
Exclusive: Pfizer approaches Medivation about potential takeover - sources
-
Sanofi (SNY) Issues Commentary on Medivation's (MDVN) Rejection of Takeover Proposal; Remains Committed to Combination
-
Sanofi Comments on Medivation's Rejection of Proposal
-
Sanofi, Medivation dig in for big biotech takeover battle
-
Sanofi Offers to Acquire Medivation (MDVN) for $52.50/Share
-
Sanofi : Sanofi Offers to Acquire Medivation for $52.50 Per Share in Cash
